Interleukin-17: Friend or foe in organ fibrosis
- PMID: 30772195
- PMCID: PMC6555688
- DOI: 10.1016/j.cyto.2018.11.003
Interleukin-17: Friend or foe in organ fibrosis
Abstract
Fibrosis affects all vital organs accounting for a staggering 45% of deaths worldwide and no effective therapies are currently available. Unresolved inflammation triggers downstream signaling events that lead to organ fibrosis. In recent years, proinflammatory cytokine Interleukin-17 (IL-17) has been implicated in several chronic inflammatory diseases that often culminate in organ damage followed by impaired wound healing and fibrosis. In this review, we outline the contribution of the IL-17 in mediating fibrotic diseases in various organs. A comprehensive understanding of the inflammatory events, and particularly the details of IL-17 signaling in vivo, could be beneficial in designing new therapeutic or preventive approaches to treat fibrosis. Additionally, understanding organ-specific differences in IL-17 activity could lead to targeted therapies and help spare other organs from unwanted side effects.
Keywords: Fibrosis; IL-17; Inflammation.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
IL-17 in lung disease: friend or foe?Thorax. 2013 Aug;68(8):788-90. doi: 10.1136/thoraxjnl-2013-203307. Epub 2013 Apr 19. Thorax. 2013. PMID: 23604380 Review.
-
γδT Cell-derived interleukin-17A via an interleukin-1β-dependent mechanism mediates cardiac injury and fibrosis in hypertension.Hypertension. 2014 Aug;64(2):305-14. doi: 10.1161/HYPERTENSIONAHA.113.02604. Hypertension. 2014. PMID: 24866139
-
IL-36 in chronic inflammation and fibrosis - bridging the gap?J Clin Invest. 2021 Jan 19;131(2):e144336. doi: 10.1172/JCI144336. J Clin Invest. 2021. PMID: 33463541 Free PMC article. Review.
-
IL-17 in Renal Immunity and Autoimmunity.J Immunol. 2018 Dec 1;201(11):3153-3159. doi: 10.4049/jimmunol.1801042. J Immunol. 2018. PMID: 30455371 Free PMC article. Review.
-
Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis.J Am Soc Nephrol. 2016 Mar;27(3):745-65. doi: 10.1681/ASN.2014111136. Epub 2015 Sep 2. J Am Soc Nephrol. 2016. PMID: 26334030 Free PMC article.
Cited by
-
Fibrosis in IBD: from pathogenesis to therapeutic targets.Gut. 2024 Apr 5;73(5):854-866. doi: 10.1136/gutjnl-2023-329963. Gut. 2024. PMID: 38233198 Review.
-
The Yin and Yang of IL-17 in Systemic Sclerosis.Front Immunol. 2022 May 4;13:885609. doi: 10.3389/fimmu.2022.885609. eCollection 2022. Front Immunol. 2022. PMID: 35603223 Free PMC article. Review.
-
Prior Trichinella spiralis infection protects against Schistosoma mansoni induced hepatic fibrosis.Front Vet Sci. 2024 Oct 8;11:1443267. doi: 10.3389/fvets.2024.1443267. eCollection 2024. Front Vet Sci. 2024. PMID: 39439825 Free PMC article.
-
Helminth egg derivatives as proregenerative immunotherapies.Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2211703120. doi: 10.1073/pnas.2211703120. Epub 2023 Feb 13. Proc Natl Acad Sci U S A. 2023. PMID: 36780522 Free PMC article.
-
Immunoregulatory Property of C-Type Lectin-Like Receptors in Fibrosing Interstitial Lung Diseases.Int J Mol Sci. 2020 May 22;21(10):3665. doi: 10.3390/ijms21103665. Int J Mol Sci. 2020. PMID: 32455964 Free PMC article. Review.
References
-
- Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B, et al. The immunology of fibrosis. Annual review of immunology. 2013;31:107–35. - PubMed
-
- Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kunkel SL, Phan SH. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine. 2003;24:266–76. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources